Valuation: Sprint Bioscience AB

Market Cap 369M 37.46M 33.55M 30.95M 28.01M 52.38M 3.57B 53.23M 147M 1.87B 141M 138M 5.91B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 369M 37.46M 33.55M 30.95M 28.01M 52.38M 3.57B 53.23M 147M 1.87B 141M 138M 5.91B EV / Sales 2026 *
4.25x
EV / Sales 2027 * 3.82x
Free-Float
72.16%
Yield 2026 *
-
Yield 2027 * -
1 day+2.86%
1 week+7.78%
Current month+5.88%
1 month+5.88%
3 months-3.49%
6 months+15.76%
Current year+144.90%
1 week 3.28
Extreme 3.28
3.7
1 month 3.25
Extreme 3.25
3.88
Current year 1.36
Extreme 1.355
4.59
1 year 0.58
Extreme 0.578
4.59
3 years 0.36
Extreme 0.36
4.59
5 years 0.36
Extreme 0.36
5.16
10 years 0.36
Extreme 0.36
37.5
Manager TitleAgeSince
Chief Executive Officer 42 01/10/2023
Chief Tech/Sci/R&D Officer 55 01/01/2009
Director of Finance/CFO 55 04/05/2026
Director TitleAgeSince
Director/Board Member 50 01/01/2019
Chairman 58 01/01/2021
Director/Board Member 70 01/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
+2.86%+7.78%+420.23%+89.47% 37.46M
-0.62%+0.50%+33.92%+60.07% 64.38B
+0.97%+3.86%+15.66%+85.73% 56.16B
+0.28%+2.15%+15.58%+107.19% 54.16B
-2.78%-4.14%+23.71%+51.16% 45.33B
+0.20%-1.23%+21.01%+99.87% 42.25B
-0.83%+1.23%+221.54%+931.55% 40.78B
+2.98%+47.20%+111.58%+95.48% 33.8B
+1.22%-1.39%+13.92%+46.95% 32.25B
-1.29%-1.72%+21.00%-6.85% 23.57B
Average +0.30%+4.70%+89.81%+156.06% 39.27B
Weighted average by Cap. -0.03%+3.64%+50.00%+161.95%

Financials

2026 *2027 *
Net sales 86.8M 8.8M 7.89M 7.28M 6.58M 12.31M 838M 12.51M 34.63M 439M 33.04M 32.34M 1.39B 96.8M 9.82M 8.79M 8.11M 7.34M 13.73M 935M 13.95M 38.62M 489M 36.85M 36.06M 1.55B
Net income - -
Net Debt - -
Projected Income Statement - Annual - Sprint Bioscience AB
Logo Sprint Bioscience AB
Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Company’s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.
Employees
32
Date Price Change Volume
30/10/26 SEK 3.600 +2.86% 16,849
29/10/26 SEK 3.500 +1.74% 299,588
28/10/26 SEK 3.440 +0.88% 85,768
27/10/26 SEK 3.410 -1.16% 102,688
26/10/26 SEK 3.450 +3.29% 228,429

Net sales - Rate of surprise

Rate of surprise - Net sales - Annual - Sprint Bioscience AB
  1. Stock Market
  2. Stocks
  3. SPRINT Stock